Lavipharm S.A. (Industrial and Commercial Corporation, Pharmaceuticals, Chemicals, Cosmetics) announces that the Annual Shareholders' Meeting held on June 28, 2007, with the participation of 16 shareholders, representing 52.24% of the share capital (20.527.204 shares), decided on the items of the agenda the following:
1. The Company's Annual Financial Statements (parent and consolidated) for the fiscal year 01.01.2006 - 31.12.2006, including the relative Reports by the Board of Directors and the Certified Auditors, were unanimously approved. The Company will distribute dividend of ? six cents (0.06 Euros) per share for the fiscal year 2006. Entitled to the dividend will be those holding shares at the closing of the Athens Stock Exchange Trading Session of August 17, 2007. As of August 20, 2007 (ex-dividend date), the share will be traded on the Athens Stock Exchange without the right to dividend for the fiscal year 2006. The dividend payment date is August 27, 2007. Dividend payment will be made in accordance to the regulations of the Athens Stock Exchange and the Central Securities Depository through EFG EUROBANK, as follows: 1. To the operators (custodians and brokerage firms) appointed by Shareholders to collect the dividend.- 2. To the Shareholders directly, via the network of EFG EUROBANK branches, upon presentation of their Identity Card, if: a) said- Shareholders hold their portfolio with the Central Securities Depository (now Hellenic Exchanges SA - H.E.L.E.X.), or b) said Shareholders have not dematerialised their shares, or c) they have not provided or have revoked the authorisation to their operator to collect the dividend. Collection of dividend by a third person is possible, as long as, that person carries in addition to the identity card, an authorization by the Shareholder where signature is certified by the Authorities (Police or other) giving full details of the beneficiary.
2. Members of the Board of Directors and the Certified Auditors were released from all liability for compensation for fiscal year 2006. The decision was taken by 11.908.812 votes, since Dr. Athanase Lavidas (representing LGH S.A.) and Panagiotis Pavlou and Dimitrios Stringas (representing ATLANTIS 2000 SA) did not participate in the resolution according to the provisions of section 35(2) of codified law (KN) 2190/1920, for the shares held by LGH S.A., and for the shares held by ATLANTIS 2000 SA respectively.
3. Remuneration of the Board of Directors members for the fiscal year 2006 was approved by 20.525.098 votes, while the maximum remuneration or/and wages for the fiscal year 01.01.2007 to 31.12.2007 were pre-approved unanimously.
4. The nomination of the auditing company KPMG PEAT MARWICK KYRIACOU was unanimously approved for the Company's regular audit of fiscal year 2007. The nomination of the auditing company SOL SA was unanimously approved for the Group's regular audit for the fiscal year 2007.
5. Authorisation was unanimously granted to the members of the Board of Directors and to the Company's Directors to participate on the Board of Directors and/or the management of other companies of the Lavipharm Group aiming at similar or resembling objectives, according to Section 23(1) of codified law (KN) 2190/1920 and to article 18 paragraph 2 of the Company's by-laws.
6. Approval was unanimously granted to enter into a Trademark License Agreement between the Company and Lavipharm Group Holding S.A. according to the provisions of Section 23 of codified law (KN) 2190/1920.
The Chairman of the Annual Meeting presented to the Shareholders the Company's developments and prospects, followed by discussion.